According to industry statistics, last week, a total of 20 domestic investment and financing projects in the medical and health field were included, including 7 and 6 investment and financing projects in the field of medical devices and
innovative drugs.
From the perspective of a single financing amount, many companies have raised more than 100 million yuan in the new week, such as Pulin Biologics and Vivis Medical
.
Among them, innovative drug company Pulin Biologics recently announced the completion of hundreds of millions of yuan financing, led by Vertex Investment, and co-invested
by Fosun Pharma and Cathay Capital.
This round of financing is mainly used for technology research and development, talent introduction, and laboratory construction
.
The company is an innovative ADC biotechnology service provider, focusing on the development of next-generation precise and flexible drug delivery systems and antibody drug conjugates (ADCs) to establish drug conjugate delivery platforms
.
The company has established a flexible and modular technology platform to synthesize ADC drug pools, and through its screening platform, it screens the optimal ADC drug composition
for each target.
Based on the connector platform that has been built with the company's independent intellectual property rights, Puling Biotech focuses on building a "First in class & Best in class" product pipeline
.
According to the company, it is expected that 1 drug will complete IND submission
in 2024.
As far as the entire field of pharmaceutical innovation is concerned, ADC drugs have unique advantages, including less "involution" than small molecule drugs and antibody drugs, and ADC drugs have better druggability, and they currently have advantages in the efficacy of solid tumors, and the industry believes that the market prospect of such drugs is broad
.
According to the data, the annual sales of global ADC drugs in 2022 were 8.
08 billion US dollars, and it is expected to increase to 22.
87 billion US dollars in 2023, with a compound growth rate of 16.
4%
from 2021 to 2030.
The field of medical devices is also relatively strong in attracting money
.
Vivis Medical is committed to building China's first "active three types of devices + data services" heart rhythm management platform
to combat sudden cardiac death.
On November 21, the company announced the completion of a pre-B round
of financing of hundreds of millions of yuan.
This round of financing was led by SDIC Venture Partners, with Dingxin Capital and Anji Liangshan co-investing
.
EC Capital acted as the sole financial advisor
to Vivis in connection with the transaction.
It is reported that the amount of financing obtained in this round will help the clinical trial of Vivis WCD products, and the heavy reserve products in the company's R&D pipeline will officially enter the prototype stage; The company's AED products will also expand production capacity, accelerate multi-category R&D and overseas sales layout
.
Domestic mass spectrometer company Anyipu also recently announced the completion of a series A financing of nearly 100 million yuan, this round of financing led by Green River Investment, followed by Dunhang Capital and Junshan Private Equity Fund of Funds, and old shareholders Fengrui Capital and Yuansheng Venture Capital continued to increase investment
.
The funds raised will be mainly used to promote the industrialization of the company's clinical ultra-high performance liquid chromatography tandem mass spectrometry system and medical device certification; Accelerate the research and development of cutting-edge clinical mass spectrometry hardware, software, and core components; Expand the industrialization team, personnel expansion, and R&D office space
.
Caixin Securities believes that under the wave of new medical infrastructure, not only the expansion of large public hospitals, but also the quality improvement and transformation of grassroots medical institutions, it can be seen that the special construction orders represented by medical purification projects and medical automation informatization projects are gradually cashed out, and the large-scale production capacity of this round of new medical infrastructure will be released one after another, and related enterprises such as medical special projects, medical equipment, and medical informatization will also benefit one after another; At the same time, in the post-epidemic era, the world has strengthened public health construction, conforming to the wave of new medical infrastructure, and also providing development opportunities
for domestic medical device products to go overseas.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
